🇺🇸 FDA

Company profile · Sponsor

TG

TG THERAPEUTICS, INC.

TGTX · NYSE pharma NEW YORK, NY, USA
Pipeline
24
Drugs
1
Patents
7

Quick answer

TG (TGTX) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 7 patents to this profile..

Company facts

Ticker TGTX
Exchange NYSE
Company type pharma
Headquarters NEW YORK, NY, USA
SEC CIK 0001001316

Pipeline (24)

Search pipeline →

  1. Fingolimod placebo, FINGOLIMOD, Ublituximab Placebo, ublituximab

    TG

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  2. Obinutuzumab

    TG

    Chronic Lymphocytic Leukemia

    phase 3 mab terminated

    1 trial

  3. Ublituximab

    TG

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    5 trials

  4. Ublituximab

    TG

    Relapsing Multiple Sclerosis (RMS)

    phase 3 mab active

    3 trials

  5. Ublituximab

    TG

    Diffuse Large B-Cell Lymphoma

    phase 3 mab terminated

    1 trial

  6. Ublituximab

    TG

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    3 trials

  7. Ublituximab, ublituximab

    TG

    Relapsing forms of Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  8. ublituximab

    TG

    relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  9. ublituximab, DEXAMETHASONE, PARACETAMOL, GADOBUTROL, ublituximab placebo, DIPHENHYDRAMINE, CETIRIZINE, METHYLPREDNISOLONE

    TG

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  10. Acalabrutinib

    TG

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  11. Pembrolizumab

    TG

    Hodgkin's Lymphoma

    phase 2 mab terminated

    1 trial

  12. TGR-1202

    TG

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  13. TGR-1202

    TG

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  14. Ublituximab

    TG

    multiple sclerosis

    phase 2 small molecule active

    1 trial

  15. Ublituximab

    TG

    Non-Hodgkins Lymphoma

    phase 2 small molecule completed

    2 trials

  16. Ublituximab

    TG

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  17. Ublituximab

    TG

    Autoimmune Disorders

    phase 2 small molecule active

    1 trial

  18. Ublituximab

    TG

    Relapsing Remitting Multiple Sclerosis

    phase 2 mab completed

    1 trial

  19. Umbralisib

    TG

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    4 trials

  20. Umbralisib

    TG

    Marginal Zone Lymphoma

    phase 2 small molecule completed

    1 trial

  21. Umbralisib

    TG

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  22. Venetoclax

    TG

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  23. Azercabtagene zapreleucel (azer-cel)

    TG

    B-cell Mediated Autoimmune Disorders

    phase 1 small molecule active

    1 trial

  24. Cosibelimab

    TG

    B-cell Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

Drugs (1)

Search drugs →

  1. ublituximab-xiiy

    BRIUMVI

    INTRAVENOUS approved

Patents (7)

Search patents →

  1. US 11965032

    Anti-CD20 antibody compositions

    Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11884740

    Anti-CD20 antibody compositions

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11814439

    Anti-CD20 antibody compositions

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11807689

    Anti-CD20 antibody compositions

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10966977

    Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10729768

    Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9694071

    Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

    Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is TG?

TG (TGTX) is a pharma company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 7 patents to this profile..

What pipeline programs does TG sponsor?

We track 24 ClinicalTrials.gov-linked programs for TG, including Fingolimod placebo, FINGOLIMOD, Ublituximab Placebo, ublituximab and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does TG company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.